1Huttin C. Experiences with reference pricing [EB/OL]. [ 2014-11-08]. http://apps.who.int/medicinedoes/en/d/ Js4912e/3.3.html.
2Sackman JE, Kuchenreuther M. Germany Post AMNOG: Insights for BioPharma [EB/OL]. [2014-12-17]. http://www. biopharminternational.com/germany-post-amnog-insights- biopharma?rel=eanonical.
3Dehnen J, Schmoeller M. 2.5 Years of amnog in germany - an analysis of benefit assessment and net price nego- tiation trends [EB/OL]. [2014-12-17]. http://www. imsconsultinggroup.com/deployedfiles/consulting/Global/ Content/Our%20Latest%20Thinking/Reeent%20Topies/ Q4%202013 %202013-10-29%20ISPOR Poster_v2.pdf.
4IHS. AOK's 2014 drug prescription report highlights success of AMNOG in reducing Germany's public pharma bill [EB/ OL]. [2014-12-17]. https://www.ihs.com/country-industry- forecasting.html?id=1065995314.
8NGORSURACHES S, MENG W,KIM BY. Drug reimbursement decisionmaking in Thailand, China, and South Korea [ J ]. Value Health ,2012,15 ( 1 Suppl) : 120 - 125.
9MCWILLIAMS P. Value-based pricing hot at ISPOR [ N ]. Phar- macoEconomics & Outcomes News : 2011 - 1 1 - 26 (642).
10KIM CY. Health technology assessment in South Korea[ J]. Int J Technol Assess Health Care ,2009,25 ( 1 ) :219 - 223.
